Patient Preferences

FDA Approves Ionis’ Dawnzera to Prevent Hereditary Angioedema Attacks

The RNA-targeting antisense shot lowers plasma prekallikrein, delivering large attack-rate reductions with four- or eight-week autoinjector dosing.